taiba rare
taiba rare is a regional specialty pharmaceutical company founded in 1980 and headquartered in Muscat, Oman, that commercializes orphan and rare disease medicines across the Middle East and Africa through in-licensing partnerships, named patient programs, and in-house distribution anchored by a Dubai Free Zone logistics hub.
- Company typePrivate
- Founded1980
- HeadquartersMuscat, Oman
- Headcount51–100
- GTM typeB2B
- OfferingServices
What taiba rare does
taiba rare (operating as Taiba Healthcare) is a regional specialty pharmaceutical company founded in 1980 in Muscat, Sultanate of Oman, specializing in the commercialization of orphan and rare disease medicines across the Middle East and Africa. The company in-licenses innovative therapies from global biotechnology partners including Alnylam, Insmed, BioMarin, Vertex, Genzyme (Sanofi), Aegerion, Elevar, and Advicenne, and commercializes a portfolio that includes RNAi therapeutics (ONPATTRO, GIVLAARI, lumasiran), inhaled antibiotics (ARIKAYCE), and renal/metabolic treatments (Sibnayal). The commercialized portfolio is complemented by Named Patient Sales (NPS) programs, through which the company provides early access to medicines not yet commercially available in-country, leveraging more than 20 years of NPS experience.
The company operates an integrated distribution model anchored by a Dubai Free Zone logistics hub capable of handling room temperature, cold chain, and freezer products, with direct in-country commercial offices in Muscat, Riyadh, Dubai, Sharjah, Doha, Kuwait City, and Cairo. Revenue is generated through licensing royalties, transfer prices on distributed product sales, and named patient program transactions, with pricing negotiated on a country-by-country basis with ministries of health and reimbursement organizations across the GCC and broader MENA region. With over 100 registered medicines and more than 40 years of regional presence, taiba rare functions as a critical access channel for biotech partners seeking MENA market entry into rare disease therapeutics.
The company is privately held with no disclosed institutional investors or public listing, and is led by CEO Saif Al Hasani. Its core competency is regulatory navigation, in-country commercial infrastructure, and centralized distribution for temperature-sensitive biologics, addressing the elevated genetic and metabolic disease burden driven by high consanguinity rates in the GCC. The business model relies on the company's regulatory depth, distribution capabilities, and brand recognition as the first regional rare disease specialist since 1980.
taiba rare firmographics
Firmographics- Name
- taiba rare
- Legal name
- Taiba Healthcare
- Website
- https://taibarare.com
- Company type
- Private
- Founded year
- 1980
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- taiba rare is a regional specialty pharmaceutical company founded in 1980 and headquartered in Muscat, Oman, that commercializes orphan and rare disease medicines across the Middle East and Africa through in-licensing partnerships, named patient programs, and in-house distribution anchored by a Dubai Free Zone logistics hub.
- Ownership category
- akta.pro rank
taiba rare industry classification
Industry- Product category
- Specialty Pharmaceuticals - Rare/Orphan Disease
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)
- akta.pro secondary industry
- Rare Infectious Disease Therapies (HLAIAIAF)
Keywords
Where taiba rare is headquartered
LocationHeadquarters
- HQ city
- Muscat
- HQ country
- Oman
- HQ region
- Middle East
Offices7 records
Markets served
taiba rare business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Licensing and Commercialization: Taiba generates revenue through licensing agreements with biotech companies for commercialization rights of orphan and rare disease medicines in the Middle East and Africa region. Revenue is earned via transfer prices and royalties from product sales.
- Named Patient Sales (NPS) Programs: As pioneers with more than 20 years of experience, Taiba provides early access medicines to patients through named patient sales programs, generating revenue from supplying medicines not yet commercially available in specific countries.
- Distribution Services: Taiba operates its own in-house distribution network serving as a central logistics hub in Dubai with Free Zone facilities. The company handles import and re-export to neighboring countries, managing cold chain products and temperature-regulated logistics.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
taiba rare product offering
Product offeringCore offering
Taiba Rare commercializes orphan and rare disease medicines across the Middle East and Africa by in-licensing innovative therapies from global biotech companies (Alnylam, Insmed, Advicenne, BioMarin, Vertex, Sanofi Genzyme, Aegerion, Elevar) and distributing them through its own regulatory registrations, in-house cold-chain logistics hub in Dubai, and Named Patient Sales programs. Its portfolio spans RNAi therapeutics, inhaled antibiotics, and renal treatments for conditions with high prevalence in GCC populations.
Product overview
taiba rare is a pharmaceutical company specializing in rare and orphan diseases in the Middle East and Africa. The company operates a portfolio of innovative medicines including commercialized RNAi therapeutics (ONPATTRO, GIVLAARI) and other orphan medicines (ARIKAYCE, Sibnayal), alongside late-stage investigational therapies like Lumasiran. The product portfolio is complemented by service offerings including Early Access/Named Patient Sales programs and integrated distribution and supply chain services through their Dubai Free Zone logistics hub. The company has more than 100 registered medicines across the region and collaborates with biotechnology partners for late-stage development through commercialization.
Differentiator
Problem solved
Functional benefit
Brands
- Access to Medicine: Patient support program focused on Named Patient Sales (NPS) programs and compassionate use of niche medicines for patients with life-threatening and orphan diseases.
Products and services
- ONPATTRO (patisiran)
- GIVLAARI (givosiran)
- ARIKAYCE (amikacin)
- Sibnayal
- Lumasiran
- Early Access / Named Patient Sales (NPS) Programs
- Pharmaceutical Distribution & Cold Chain Logistics
Quantifiable outcome
- More than 20 years of experience in early access/named patient sales programs
- +2 more outcomes
Companies that use taiba rare
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
taiba rare technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
taiba rare partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- AdvicennecoreFirst distribution agreement outside Europe for Sibnayal (distal Renal Tubular Acidosis treatment). Taiba receives exclusive marketing rights in defined territories and is working on early access program. Advicenne receives transfer price and royalties exceeding 50% of future sales. Taiba and Advicenne responsible for local product registration based on European marketing authorization.
- Insmed BVcoreCommercialization agreement for ARIKAYCE in GCC countries. This expands the partnership for commercialization following initial agreement.
- Insmed Netherlands BV (Insmed Incorporated)coreExclusive rights granted to Taiba to market and distribute ARIKAYCE (amikacin) in GCC countries (Saudi Arabia, UAE, Kuwait, Oman, Qatar, Bahrain). Taiba responsible for named patient supply program with intent to commercialize following marketing authorization. ARIKAYCE approved in US, EU, UK, and Japan for refractory MAC lung disease, with Orphan Drug Designation and Breakthrough Therapy Designation.
- Elevar TherapeuticsminorCooperation agreement for Middle East - North Africa region. Nature of partnership related to distribution and commercialization of specialty medicines.
- Alnylam PharmaceuticalscoreDistribution agreement for RNAi therapeutics ONPATTRO (hATTR amyloidosis) and GIVLAARI (acute hepatic porphyria), plus lumasiran (late-stage therapy for Primary Hyperoxaluria Type 1) across Gulf states including Kingdom of Saudi Arabia, Kuwait, Bahrain, Qatar, Oman, and UAE. The cooperation addresses unmet medical needs of rare disease patients in the Middle East region where certain diseases have higher regional prevalence.
- Aegerion (Ionis/Aegerion Pharmaceuticals)minorTaiba represents Aegerion, a pioneer in rare disease therapeutics, as part of their portfolio of leading multinational biotech companies.
- BioMarinminorTaiba represents BioMarin as part of their rare disease portfolio of leading multinational biotech companies.
- Genzyme (Sanofi Genzyme)minorTaiba represents Genzyme, a pioneer in rare disease therapeutics, as part of their portfolio.
- Vertex PharmaceuticalsminorTaiba represents Vertex Pharmaceuticals as part of their rare disease portfolio of leading multinational biotech companies.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
taiba rare competitors and assessment
Company assessmentDirect peers
- Genpharm: Middle East-based specialty pharmaceutical company focused on rare diseases and genetic disorders across the MENA region. Most direct regional competitor with comparable focus on orphan drug commercialization and named patient access programs.
Regional players
- Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer and distributor with broad Gulf market presence. Comparable as a regional pharma player operating across GCC healthcare systems, though focused on generics and consumer health rather than rare diseases.
- EIPICO: One of Egypt's largest pharmaceutical manufacturers and distributors, serving both private and public healthcare channels. Comparable as a regional pharma with multi-country MENA presence, though focused on mass-market and generic products.
- Tabuk Pharmaceuticals: Saudi pharmaceutical company with branded generics, specialty, and biotech partnerships across MENA. Comparable regional sales, distribution, and partnership-driven model, with growing presence in specialty therapeutics.
- Algorithm Pharma: Lebanon-based specialty pharmaceutical company with MENA distribution across rare diseases, oncology, and specialty therapeutics. Comparable regional in-licensing and named-patient distribution model for orphan and specialty medicines.
- SPIMACO: Saudi Arabia's leading pharmaceutical manufacturer with broad specialty and branded generics portfolio. Comparable as a Gulf-based pharma company serving ministries of health and regional reimbursement systems, though primarily a manufacturer.
Broad incumbents
- Hikma Pharmaceuticals: One of the largest MENA-headquartered pharmaceutical companies with branded generics, injectables, and specialty portfolios. Comparable regional distribution footprint and hospital/channel reach, though rare diseases are a small part of its broader portfolio.
- Sobi (Swedish Orphan Biovitrum): Global rare disease specialty pharmaceutical company with established Middle East presence. Comparable as a pure-play orphan drug company that relies on in-licensing and partnerships, though operating at much larger scale across multiple regions.
- Kyowa Kirin: Japan-headquartered global specialty pharma focused on rare and serious diseases. Comparable as a partner-side analog (rare disease innovator) and as an indirect competitor for partnership mandates from biotech licensors.
- Recordati Rare Diseases: Specialty pharma division of Recordati focused on rare diseases globally, with established European and emerging-market distribution. Comparable as an established orphan drug distributor with named-patient program expertise.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
taiba rare social profiles
Digital presencetaiba rare financial estimates
Financial estimateRevenue estimate
Valuation estimate
taiba rare leadership team
Management profileNumber of profiles
Profiles1 record
taiba rare subsidiaries and ownership
Company hierarchySubsidiaries7 records
taiba rare funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
taiba rare M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about taiba rare
What does taiba rare do?
Taiba Rare commercializes orphan and rare disease medicines across the Middle East and Africa by in-licensing innovative therapies from global biotech companies (Alnylam, Insmed, Advicenne, BioMarin, Vertex, Sanofi Genzyme, Aegerion, Elevar) and distributing them through its own regulatory registrations, in-house cold-chain logistics hub in Dubai, and Named Patient Sales programs. Its portfolio spans RNAi therapeutics, inhaled antibiotics, and renal treatments for conditions with high prevalence in GCC populations.
Is taiba rare a public or private company?
taiba rare is a private company. It is classified as unknown and is currently operating.
When was taiba rare founded?
taiba rare was founded in 1980. It employs 51 to 100 people.
Where is taiba rare based?
taiba rare is headquartered in Muscat, Oman, in the Middle East region.
How does taiba rare make money?
Three revenue lines are on record. Licensing and Commercialization is the primary driver. The others are named Patient Sales (NPS) Programs and distribution Services.
Who are taiba rare's main competitors?
Genpharm is listed as a direct peer. Regional players are Julphar (Gulf Pharmaceutical Industries), EIPICO, Tabuk Pharmaceuticals, Algorithm Pharma and SPIMACO. Broad incumbents are Hikma Pharmaceuticals, Sobi (Swedish Orphan Biovitrum), Kyowa Kirin and Recordati Rare Diseases.
Does taiba rare have an API?
No public API is recorded for taiba rare.
What industry is taiba rare in?
taiba rare's product category is Specialty Pharmaceuticals - Rare/Orphan Disease. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics, with a secondary code of HLAIAIAF, Rare Infectious Disease Therapies. Its NAICS code is 42421 and its SIC code is 2836.